Trevi Therapeutics (NASDAQ:TRVI) Earns Outperform Rating from Analysts at Leerink Partners
Leerink Partners began coverage on shares of Trevi Therapeutics (NASDAQ:TRVI – Free Report) in a research report released on Monday morning, Marketbeat.com reports. The brokerage issued an outperform rating and a $7.00 price objective on the stock. Other research analysts also recently issued research reports about the company. Rodman & Renshaw began coverage on Trevi […]
More Stories
DEI Practices Reduce Productivity, Cost $94 Billion Annually: White House Economic Report
By Travis Gillmore WASHINGTON—Diversity, equity, and inclusion practices negatively impacted the U.S. economy, according to the 2026 White House Economic...
Fauci Deputy Who Declined COVID-19 Vaccine Feared Retaliation: Emails
By Zachary Stieber A top government doctor who declined to receive a COVID-19 vaccine in 2021 was worried he would...
20+ SEO Checklist For Blog Posts: Read Before Publishing
You wrote a fantastic blog. What’s next? Publishing blogs without optimizing them for SEO is like starting a shop without...
US Military Blockade on Iranian Ports Goes Into Effect, Maritime Group Says
By Jack Phillips A scheduled U.S. naval blockade of the Strait of Hormuz and nearby waters started at 10 a.m....
Who is Jonathan Joly? Age, Marriage, and Net Worth in 2026
If you like to scroll on social media, the chances of you witnessing Jonathan Joly are high. Are you also...
Rory McIlroy Wins Back-to-Back Masters Titles to Join Jack Nicklaus, Nick Faldo, and Tiger Woods
By The Associated Press AUGUSTA, Ga.—Rory McIlroy joined more elite company Sunday at the Masters when he pulled away with...